Pharmaceuticals & Drugs · Founded 1989 · www.advancedenzymes.com · BSE 540025 · NSE ADVENZYMES · ISIN INE837H01020
No Notes Added Yet
Business
Advanced Enzyme Technologies Ltd. (ADVENZYMES) is a research and development-driven company primarily engaged in the manufacturing and marketing of enzymes and enzyme blends. The company develops, manufactures, and supplies over 400 proprietary enzyme products across 68 countries. Its core business model involves leveraging its expertise in microbial fermentation and enzyme technology to produce specialty enzymes used in various industries. The company makes money by selling these enzyme products to B2B customers in sectors like human nutrition (digestive aids, probiotics, nutraceuticals), animal nutrition (feed enzymes), industrial applications (textile, food & beverage processing, biofuels), and bio-processing.
Revenue Mix
The company broadly categorizes its products into:
Human Nutrition: This segment focuses on enzymes for digestive health, immunity, anti-inflammatory applications, and probiotics for supplements, functional foods, and pharmaceutical applications. This is typically the largest revenue contributor.
Animal Nutrition: Enzymes used in animal feed to improve digestion, nutrient absorption, and overall animal health.
Bio-processing & Industrial Applications: Enzymes tailored for use in various industrial processes such as food & beverage processing (dairy, baking, brewing), textile processing, waste management, and biofuels.
While specific contribution percentages fluctuate, Human Nutrition generally constitutes the largest portion of revenue, followed by Animal Nutrition and Industrial applications.
Industry
Advanced Enzyme Technologies operates in the global enzyme industry, which is a niche but growing part of the broader biotechnology and specialty chemicals sector. The industry is characterized by significant R&D investment, technical expertise, and stringent quality standards. Globally, it competes with large multinational players like Novozymes, IFF (DuPont Nutrition & Biosciences), DSM, and BASF, as well as several smaller, specialized enzyme manufacturers. ADVENZYMES is one of India's largest enzyme manufacturers and is positioned as a leading player in specific enzyme categories globally, particularly in digestive enzymes and certain nutraceutical formulations. Its strength lies in its extensive product portfolio, proprietary enzyme strains, and ability to customize solutions.
MOAT
R&D and Proprietary Technology: The company has a strong focus on R&D, leading to the development of proprietary enzyme strains and manufacturing processes. This creates barriers to entry for competitors.
Comprehensive Product Portfolio: A wide range of 400+ enzyme products caters to diverse applications, allowing for cross-selling and diversified revenue streams.
Quality & Regulatory Compliance: Adherence to global quality standards (e.g., USFDA, FSSC 22000, ISO 22000, HALAL, KOSHER) ensures product acceptance in regulated markets and builds customer trust.
Customer Stickiness: For specific industrial applications, switching enzyme suppliers can be costly and time-consuming due to the need for re-validation and process adjustments.
Manufacturing Scale and Cost Efficiency: Operating large-scale fermentation facilities allows for economies of scale, potentially leading to competitive pricing.
Growth Drivers
Rising Demand in Human Nutrition: Growing consumer awareness about health, wellness, digestive health, and immunity drives demand for nutraceuticals, probiotics, and enzyme supplements.
Growth in Animal Feed Industry: Increasing global meat and dairy consumption fuels demand for feed enzymes to improve feed conversion ratios and reduce antibiotic usage.
Shift Towards Bio-based Solutions: A global trend towards replacing chemical processes with eco-friendly enzyme-based solutions across various industries (food, textiles, biofuels).
Geographic Expansion: Penetration into new international markets and strengthening presence in existing ones, especially in regions with growing middle-class populations.
New Product Development: Continuous innovation and launch of novel enzymes for new applications or improved efficacy.
Risks
Raw Material Price Volatility: Key raw materials for fermentation (e.g., corn, soy, molasses) are agricultural commodities, subject to price fluctuations.
Intense Competition & Pricing Pressure: The presence of large global players and several regional competitors can lead to pricing pressure and impact profitability.
Regulatory Changes: Stricter regulations in the food, pharmaceutical, and animal feed industries in various countries could impact product approvals and market access.
Technological Obsolescence: Rapid advancements in biotechnology mean that existing enzyme products or production methods could become obsolete if competitors introduce superior alternatives.
Dependency on End-Use Industries: Performance is linked to the growth and health of the nutraceutical, animal feed, and industrial sectors, which can be cyclical.
Foreign Exchange Fluctuations: Significant international sales expose the company to currency exchange rate risks.
Management & Ownership
Advanced Enzyme Technologies is a promoter-led company with Mr. V. C. Rathi (Chairman & Managing Director) and Mr. C. L. Rathi (Jt. Managing Director) being key figures from the promoter group. The management team generally possesses long-standing experience in the enzyme and biotechnology sectors. The ownership structure typically includes a significant promoter holding, institutional investors (both domestic and foreign), and public shareholders. The promoter's deep industry knowledge and strategic vision are often cited as strengths.
Outlook
Advanced Enzyme Technologies is well-positioned to capitalize on the secular growth trends in the global enzyme market, driven by increasing demand for health and wellness products, sustainable industrial solutions, and efficient animal nutrition. Its strong R&D capabilities, diverse product portfolio, and established global presence provide a solid foundation for future growth. However, the company operates in a competitive and technically demanding industry. Success will depend on its ability to continuously innovate, manage raw material costs, navigate complex regulatory landscapes, and effectively compete with both global giants and specialized players. While the underlying demand drivers are favorable, potential challenges from intense competition, R&D success rates, and macroeconomic factors remain important considerations.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 158 | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 190 |
| Other Income | 9 | 7 | 10 | 8 | 9 | 9 | 10 | 8 | 7 | 13 |
| Total Income | 167 | 162 | 156 | 177 | 176 | 195 | 195 | 180 | 211 | 203 |
| Total Expenditure | 102 | 103 | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 |
| Operating Profit | 65 | 58 | 52 | 63 | 54 | 65 | 70 | 58 | 70 | 64 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 |
| Exceptional Income / Expenses | -15 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 0 |
| Profit Before Tax | 40 | 49 | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 |
| Provision for Tax | 10 | 14 | 9 | 14 | 17 | 14 | 15 | 15 | 15 | 15 |
| Profit After Tax | 30 | 35 | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 |
| Adjustments | -2 | -1 | -1 | -1 | -0 | -1 | -1 | -1 | -2 | -1 |
| Profit After Adjustments | 28 | 34 | 33 | 38 | 26 | 40 | 43 | 43 | 43 | 37 |
| Adjusted Earnings Per Share | 2.5 | 3.1 | 2.9 | 3.4 | 2.4 | 3.6 | 3.9 | 3.8 | 3.8 | 3.3 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 294 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 746 | 750 |
| Other Income | 1 | 3 | 3 | 6 | 6 | 9 | 6 | 25 | 37 | 33 | 36 | 38 |
| Total Income | 295 | 332 | 394 | 425 | 450 | 511 | 536 | 566 | 661 | 670 | 782 | 789 |
| Total Expenditure | 156 | 178 | 227 | 237 | 241 | 269 | 327 | 383 | 419 | 441 | 516 | 526 |
| Operating Profit | 139 | 154 | 166 | 188 | 209 | 241 | 209 | 183 | 242 | 229 | 265 | 262 |
| Interest | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 3 | 4 | 5 | 4 | 4 |
| Depreciation | 9 | 13 | 18 | 21 | 26 | 29 | 35 | 35 | 35 | 37 | 40 | 40 |
| Exceptional Income / Expenses | -4 | 0 | 0 | 0 | 0 | 0 | 0 | -4 | -15 | 0 | 11 | 11 |
| Profit Before Tax | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 | 188 | 187 | 233 | 232 |
| Provision for Tax | 41 | 44 | 45 | 46 | 46 | 59 | 47 | 37 | 51 | 53 | 59 | 60 |
| Profit After Tax | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 134 | 174 | 172 |
| Adjustments | -1 | -1 | -3 | -5 | -4 | -5 | -4 | 2 | -4 | -3 | -5 | -5 |
| Profit After Adjustments | 76 | 92 | 90 | 111 | 129 | 146 | 120 | 106 | 133 | 131 | 169 | 166 |
| Adjusted Earnings Per Share | 7 | 8.2 | 8.1 | 9.9 | 11.6 | 13.1 | 10.7 | 9.4 | 11.9 | 11.7 | 15.1 | 14.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 17% | 11% | 8% | 10% |
| Operating Profit CAGR | 16% | 13% | 2% | 7% |
| PAT CAGR | 30% | 19% | 3% | 8% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -16% | -7% | -8% | -5% |
| ROE Average | 11% | 11% | 11% | 16% |
| ROCE Average | 15% | 15% | 15% | 22% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 278 | 464 | 559 | 679 | 840 | 971 | 1089 | 1235 | 1324 | 1421 | 1632 |
| Minority's Interest | 5 | 21 | 23 | 26 | 28 | 62 | 52 | 49 | 47 | 48 | 51 |
| Borrowings | 39 | 19 | 20 | 7 | 4 | 10 | 8 | 8 | 7 | 9 | 8 |
| Other Non-Current Liabilities | 17 | 13 | 23 | 23 | 35 | 39 | 51 | 41 | 37 | 37 | 36 |
| Total Current Liabilities | 111 | 62 | 99 | 65 | 60 | 68 | 60 | 78 | 106 | 96 | 107 |
| Total Liabilities | 450 | 583 | 727 | 805 | 971 | 1149 | 1260 | 1411 | 1521 | 1611 | 1834 |
| Fixed Assets | 285 | 421 | 491 | 495 | 563 | 604 | 619 | 649 | 650 | 679 | 692 |
| Other Non-Current Assets | 25 | 18 | 21 | 23 | 28 | 29 | 37 | 39 | 62 | 53 | 98 |
| Total Current Assets | 140 | 138 | 211 | 282 | 376 | 516 | 604 | 722 | 810 | 880 | 1044 |
| Total Assets | 450 | 583 | 727 | 805 | 971 | 1149 | 1260 | 1411 | 1521 | 1611 | 1834 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 4 | 25 | 8 | 61 | 23 | 83 | 192 | 267 | 96 | 114 | 94 |
| Cash Flow from Operating Activities | 93 | 107 | 116 | 129 | 141 | 163 | 122 | 140 | 141 | 142 | 157 |
| Cash Flow from Investing Activities | -5 | -60 | -78 | -125 | -44 | -26 | -4 | -298 | -65 | -89 | -74 |
| Cash Flow from Financing Activities | -63 | -65 | -2 | -43 | -39 | -26 | -49 | -26 | -59 | -73 | -70 |
| Net Cash Inflow / Outflow | 26 | -18 | 36 | -39 | 58 | 111 | 70 | -184 | 17 | -19 | 12 |
| Closing Cash & Cash Equivalent | 25 | 8 | 61 | 23 | 83 | 192 | 267 | 96 | 114 | 94 | 109 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 6.97 | 8.2 | 8.08 | 9.95 | 11.58 | 13.06 | 10.7 | 9.45 | 11.92 | 11.72 | 15.07 |
| CEPS(Rs) | 7.85 | 9.47 | 10.02 | 12.27 | 14.22 | 16.11 | 14.2 | 12.42 | 15.4 | 15.24 | 19.09 |
| DPS(Rs) | 0.2 | 0.4 | 0.5 | 0.6 | 0.6 | 0.9 | 1 | 1 | 5.1 | 5.2 | 5.35 |
| Book NAV/Share(Rs) | 25.55 | 41.54 | 49.85 | 60.49 | 74.86 | 86.67 | 97.31 | 110.45 | 118.14 | 126.56 | 144.99 |
| Core EBITDA Margin(%) | 45.18 | 44.14 | 41.34 | 43.5 | 45.74 | 46.74 | 38.19 | 29.09 | 32.87 | 30.7 | 30.69 |
| EBIT Margin(%) | 41.4 | 41.24 | 37.42 | 39.83 | 41.26 | 42.75 | 32.8 | 26.57 | 30.73 | 30.15 | 31.62 |
| Pre Tax Margin(%) | 38.82 | 39.95 | 35.13 | 38.59 | 40.34 | 42.23 | 32.25 | 25.93 | 30.07 | 29.42 | 31.12 |
| PAT Margin (%) | 25.21 | 27.09 | 23.65 | 27.62 | 29.96 | 30.41 | 23.34 | 19.18 | 21.92 | 21.04 | 23.24 |
| Cash Profit Margin (%) | 28.07 | 30.81 | 28.27 | 32.65 | 35.76 | 36.18 | 29.93 | 25.65 | 27.57 | 26.77 | 28.6 |
| ROA(%) | 17.81 | 18 | 14.28 | 15.13 | 14.98 | 14.27 | 10.28 | 7.78 | 9.34 | 8.55 | 10.08 |
| ROE(%) | 31.32 | 25.06 | 18.34 | 18.82 | 17.61 | 16.77 | 12.04 | 8.94 | 10.72 | 9.79 | 11.43 |
| ROCE(%) | 35.68 | 31.53 | 25.88 | 24.96 | 23.21 | 22.93 | 16.66 | 12.26 | 14.78 | 13.76 | 15.27 |
| Receivable days | 47.26 | 48.73 | 50.01 | 51.02 | 54.83 | 59.04 | 60.03 | 63.55 | 58.11 | 61.31 | 63.61 |
| Inventory Days | 67.81 | 68.6 | 66.45 | 66.31 | 64.49 | 63.79 | 73.9 | 82.55 | 79.59 | 87.61 | 81.73 |
| Payable days | 68.75 | 57.95 | 63.8 | 64.17 | 43.59 | 45.81 | 55.08 | 58.32 | 50.47 | 42.35 | 56.22 |
| PER(x) | 0 | 50.25 | 26.38 | 18.39 | 12.36 | 26.4 | 26.37 | 24.52 | 29.15 | 23.8 | 16.94 |
| Price/Book(x) | 0 | 9.92 | 4.27 | 3.02 | 1.91 | 3.98 | 2.9 | 2.1 | 2.94 | 2.2 | 1.76 |
| Dividend Yield(%) | 0 | 0.1 | 0.23 | 0.33 | 0.42 | 0.26 | 0.35 | 0.43 | 1.47 | 1.86 | 2.09 |
| EV/Net Sales(x) | 0.33 | 14.12 | 6.1 | 4.89 | 3.47 | 7.32 | 5.46 | 4.59 | 6.07 | 4.76 | 3.71 |
| EV/Core EBITDA(x) | 0.7 | 30.12 | 14.33 | 10.91 | 7.37 | 15.22 | 13.83 | 13.56 | 15.62 | 13.28 | 10.43 |
| Net Sales Growth(%) | 31.67 | 11.99 | 18.85 | 7.31 | 5.81 | 13.03 | 5.49 | 2.13 | 15.4 | 2.09 | 17.09 |
| EBIT Growth(%) | 49.93 | 12.26 | 4.63 | 12.93 | 9.61 | 16.08 | -18.19 | -17.32 | 33.42 | 0.03 | 23.06 |
| PAT Growth(%) | 48.12 | 21.1 | 0.66 | 23.89 | 14.79 | 13.71 | -18.17 | -16.1 | 31.85 | -2.17 | 29.58 |
| EPS Growth(%) | 48.78 | 17.64 | -1.5 | 23.16 | 16.39 | 12.82 | -18.11 | -11.68 | 26.19 | -1.69 | 28.63 |
| Debt/Equity(x) | 0.36 | 0.12 | 0.12 | 0.05 | 0.03 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
| Current Ratio(x) | 1.26 | 2.24 | 2.13 | 4.33 | 6.31 | 7.64 | 10 | 9.31 | 7.61 | 9.14 | 9.78 |
| Quick Ratio(x) | 0.72 | 1.13 | 1.37 | 3.15 | 4.96 | 6.25 | 8 | 7.71 | 6.22 | 7.51 | 8.12 |
| Interest Cover(x) | 16.04 | 31.91 | 16.34 | 32.13 | 44.94 | 82.76 | 58.89 | 41.36 | 46.58 | 41.44 | 63.28 |
| Total Debt/Mcap(x) | 0 | 0.01 | 0.03 | 0.02 | 0.02 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 43.02 | 42.95 | 42.93 | 43.08 | 43.08 | 43.07 | 43.04 | 43.26 | 43.24 | 43.56 |
| FII | 12.03 | 12.63 | 12.58 | 11.9 | 23.46 | 25.41 | 25.86 | 25.49 | 26.71 | 26.65 |
| DII | 8.08 | 8.02 | 8.17 | 8.19 | 8.45 | 6.41 | 5.51 | 5.41 | 4.78 | 1.89 |
| Public | 36.88 | 36.41 | 36.32 | 36.83 | 25.02 | 25.1 | 25.6 | 25.84 | 25.27 | 27.9 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.81 | 4.8 | 4.8 | 4.82 | 4.82 | 4.82 | 4.82 | 4.84 | 4.84 | 4.84 |
| FII | 1.34 | 1.41 | 1.41 | 1.33 | 2.62 | 2.84 | 2.89 | 2.85 | 2.99 | 2.96 |
| DII | 0.9 | 0.9 | 0.91 | 0.92 | 0.94 | 0.72 | 0.62 | 0.61 | 0.54 | 0.21 |
| Public | 4.12 | 4.07 | 4.06 | 4.12 | 2.8 | 2.81 | 2.87 | 2.89 | 2.83 | 3.1 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11.18 | 11.18 | 11.19 | 11.19 | 11.19 | 11.19 | 11.19 | 11.19 | 11.2 | 11.12 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +17% | +11% | +8% | +10% |
| Operating Profit CAGR | +16% | +13% | +2% | +7% |
| PAT CAGR | +30% | +19% | +3% | +8% |
| Share Price CAGR | -16% | -7% | -8% | -5% |
| ROE Average | +11% | +11% | +11% | +16% |
| ROCE Average | +15% | +15% | +15% | +22% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 43.02 | 42.95 | 42.93 | 43.08 | 43.08 | 43.07 | 43.04 | 43.26 | 43.24 | 43.56 |
| FII | 12.03 | 12.63 | 12.58 | 11.9 | 23.46 | 25.41 | 25.86 | 25.49 | 26.71 | 26.65 |
| DII | 8.08 | 8.02 | 8.17 | 8.19 | 8.45 | 6.41 | 5.51 | 5.41 | 4.78 | 1.89 |
| Public | 36.88 | 36.41 | 36.32 | 36.83 | 25.02 | 25.1 | 25.6 | 25.84 | 25.27 | 27.9 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.81 | 4.8 | 4.8 | 4.82 | 4.82 | 4.82 | 4.82 | 4.84 | 4.84 | 4.84 |
| FII | 1.34 | 1.41 | 1.41 | 1.33 | 2.62 | 2.84 | 2.89 | 2.85 | 2.99 | 2.96 |
| DII | 0.9 | 0.9 | 0.91 | 0.92 | 0.94 | 0.72 | 0.62 | 0.61 | 0.54 | 0.21 |
| Public | 4.12 | 4.07 | 4.06 | 4.12 | 2.8 | 2.81 | 2.87 | 2.89 | 2.83 | 3.1 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11.18 | 11.18 | 11.19 | 11.19 | 11.19 | 11.19 | 11.19 | 11.19 | 11.2 | 11.12 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.